David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Hey, AMC Stock Investors! Don’t Monkey Around With APE Shares.

By David Moadel, InvestorPlace Contributor

Volatility is likely to be the rule, not the exception, as AMC stock traders aren't too pleased with a large-scale preferred equity sale.

Why Is Clovis Oncology (CLVS) Stock Up Today?

By David Moadel, InvestorPlace Contributor

CLVS stock just caught a bid as Clovis advances potential treatment options for men's disease that deserves the medical community's attention.

NCLH Stock Alert: What to Know as Norwegian Cruise Line Drops Covid-19 Precautions

By David Moadel, InvestorPlace Contributor

NCLH stock got a nice bump, and there's the potential for an even bigger move as Norwegian relaxes some safety requirements.

Why It’s a Great Time to Buy (a Small Bit) of SOFI Stock

By David Moadel, InvestorPlace Contributor

SOFI stock looks undervalued as the neo-finance disruptor offers an array of resources for open-minded bankers and investors.

Why Is Intercept Pharmaceuticals (ICPT) Stock Down 20% Today?

By David Moadel, InvestorPlace Contributor

Market traders watched Intercept's recent clinical trial with anticipation. Unfortunately, the results fell short and ICPT stock is tanking.

Load More